Einzeltreffer — DigiBib

The prevalence of obesity-associated conditions raises new challenges in clinical medication. Although altered expression of drug-metabolizing enzymes (DMEs) has been shown in obesity, the impacts of obese levels (overweight, obesity, and severe obesity) on the expression of DMEs have not been elucidated. Especially, limited information is available on whether parental obese levels affect ontogenic expression of DMEs in children. Here, a high-fat diet (HFD) and three feeding durations were used to mimic different obese levels in C57BL/6 mice. The hepatic expression of five nuclear receptors (NRs) and nine DMEs was examined. In general, a trend of induced expression of NRs and DMEs (except for Cyp2c29 and 3a11 ) was observed in HFD groups compared to low-fat diet (LFD) groups. Differential effects of HFD on the hepatic expression of DMEs were found in adult mice at different obese levels. Family-based dietary style of an HFD altered the ontogenic expression of DMEs in the offspring older than 15 days. Furthermore, obese levels of parental mice affected the hepatic expression of DMEs in offspring. Overall, the results indicate that obese levels affected expression of the DMEs in adult individuals and that of their children. Drug dosage might need to be optimized based on the obese levels.

Titel:	Impact of obese levels on the hepatic expression of nuclear receptors and drug-metabolizing enzymes in adult and offspring mice.
Autor/in / Beteiligte Person:	Wang, P ; Shao, X ; Bao, Y ; Zhu, J ; Chen, L ; Zhang, L ; Ma, X ; Zhong, XB
Link:	Full Text Finder (Volltext)
Zeitschrift:	Acta pharmaceutica Sinica. B, Jg. 10 (2020), Heft 1, S. 171-185
Veröffentlichung:	[Amsterdam] : Elsevier, 2011-, 2020
Medientyp:	academicJournal
ISSN:	2211-3835 (print)
DOI:	10.1016/j.apsb.2019.10.009
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Acta Pharm Sin B] 2020 Jan; Vol. 10 (1), pp. 171-185. <i>Date of Electronic Publication: </i>2019 Nov 28. References: J Dev Orig Health Dis. 2014 Jun;5(3):229-39. (PMID: 24901663) ; Clin Pharmacokinet. 2016 Jul;55(7):833-847. (PMID: 26818482) ; Arch Biochem Biophys. 2015 Apr 1;571:21-39. (PMID: 25703193) ; Acta Pharm Sin B. 2019 Jul;9(4):758-768. (PMID: 31384536) ; Front Physiol. 2018 Jan 04;8:1117. (PMID: 29354072) ; PLoS One. 2012;7(10):e47713. (PMID: 23091640) ; Placenta. 2012 Dec;33(12):1045-51. (PMID: 23046808) ; Obesity (Silver Spring). 2018 May;26(5):814-818. (PMID: 29626388) ; Anal Biochem. 2019 Aug 1;578:45-50. (PMID: 31075230) ; PLoS One. 2013;8(1):e53038. (PMID: 23301016) ; Pharm Res. 2006 Jun;23(6):1188-200. (PMID: 16715367) ; Br J Clin Pharmacol. 2018 Aug;84(8):1738-1747. (PMID: 29618168) ; Sci Rep. 2012;2:799. (PMID: 23150771) ; Int J Obes (Lond). 2010 Apr;34(4):712-9. (PMID: 20065960) ; Shock. 2016 Apr;45(4):349-58. (PMID: 26513706) ; Nutr Res Rev. 2010 Dec;23(2):270-99. (PMID: 20977819) ; BMC Genomics. 2017 Apr 18;18(1):305. (PMID: 28420336) ; Diabetes Metab Syndr. 2019 Jan - Feb;13(1):318-321. (PMID: 30641719) ; Biol Pharm Bull. 2006 Aug;29(8):1634-8. (PMID: 16880618) ; Clin Pharmacokinet. 2014 Oct;53(10):931-41. (PMID: 25141974) ; Drug Metab Dispos. 2018 Aug;46(8):1241-1250. (PMID: 29884652) ; J Hepatol. 2013 Apr;58(4):824-6. (PMID: 23298629) ; Endocrinology. 2017 Aug 1;158(8):2407-2419. (PMID: 28586412) ; PLoS One. 2014 Aug 29;9(8):e106159. (PMID: 25170916) ; Eur J Gastroenterol Hepatol. 2008 Sep;20(9):843-54. (PMID: 18794597) ; J Drug Metab Toxicol. 2012;3(3):1000119. (PMID: 29177108) ; Curr Protoc Pharmacol. 2012 Sep;Chapter 5:Unit5.61. (PMID: 22948848) ; N Engl J Med. 2017 Jul 6;377(1):13-27. (PMID: 28604169) ; Acta Pharm Sin B. 2017 Jul;7(4):427-438. (PMID: 28752027) ; Clin Pharmacokinet. 2012 May 1;51(5):277-304. (PMID: 22448619) ; J Biomed Biotechnol. 2011;2011:197636. (PMID: 21274264) ; Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):19-24. (PMID: 29148111) ; J Family Med Prim Care. 2015 Apr-Jun;4(2):187-92. (PMID: 25949965) ; Physiol Rep. 2017 Apr;5(7):. (PMID: 28408640) ; Dig Dis. 2010;28(1):155-61. (PMID: 20460905) ; FEBS Lett. 2009 Dec 17;583(24):3966-73. (PMID: 19850042) ; Toxicol Sci. 2018 Jul 1;164(1):218-228. (PMID: 29596651) ; Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt A):2067-2077. (PMID: 29526820) ; Drug Metab Dispos. 2013 Apr;41(4):844-57. (PMID: 23382457) ; Epigenomics. 2018 Jan;10(1):43-57. (PMID: 29172698) ; Drug Metab Dispos. 2012 Jun;40(6):1198-209. (PMID: 22434873) ; Arch Med Sci. 2016 Aug 1;12(4):906-14. (PMID: 27478474) ; Toxicology. 2018 Dec 1;410:199-213. (PMID: 30120929) ; Int J Mol Sci. 2016 Jun 15;17(6):. (PMID: 27314342) ; Life Sci. 2015 Jul 15;133:15-20. (PMID: 25998026) ; Br J Nutr. 2015 Feb 14;113(3):507-16. (PMID: 25612518) ; Acta Pharm Sin B. 2019 Mar;9(2):220-236. (PMID: 30976490) ; Gastroenterol Hepatol (N Y). 2010 Dec;6(12):780-92. (PMID: 21301632) ; Obesity (Silver Spring). 2013 Apr;21(4):815-23. (PMID: 23712985) ; Nat Rev Endocrinol. 2018 Mar;14(3):140-162. (PMID: 29348476) ; Biochem Pharmacol. 2019 Jun;164:368-376. (PMID: 31063713) ; Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Jun;161(2):144-151. (PMID: 28546638) ; Biol Pharm Bull. 2013;36(4):649-57. (PMID: 23358370) ; Pharmacotherapy. 2017 Mar;37(3):361-378. (PMID: 28079262) ; Gynecol Endocrinol. 2014 Feb;30(2):90-4. (PMID: 24188449) ; Curr Drug Metab. 2013 Dec;14(10):1059-69. (PMID: 24329114) ; PLoS One. 2015 Apr 17;10(4):e0120775. (PMID: 25886196) ; Diabetes. 2015 Jun;64(6):2092-103. (PMID: 25576054) ; Drug Metab Dispos. 2017 Jul;45(7):707-711. (PMID: 28442500) ; Clin Pharmacol Ther. 2013 Mar;93(3):275-82. (PMID: 23361102) ; J Pharmacol Exp Ther. 2003 Jul;306(1):287-300. (PMID: 12676886) ; World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253. (PMID: 11234459) ; Diabetes. 2010 Sep;59(9):2178-87. (PMID: 20547980) ; Lancet. 2017 Dec 16;390(10113):2627-2642. (PMID: 29029897) ; Lipids. 2017 Jun;52(6):499-511. (PMID: 28429150) ; Physiol Rep. 2017 Apr;5(7):. (PMID: 28400497) ; Mayo Clin Proc. 2017 Feb;92(2):251-265. (PMID: 28065514) ; Int J Cardiol. 2017 Jan 15;227:89-93. (PMID: 27855292) ; Environ Sci Technol. 2017 Aug 15;51(16):9334-9343. (PMID: 28723108) ; Drug Metab Dispos. 2010 Dec;38(12):2252-8. (PMID: 20736321) ; Life Sci. 2011 Jul 4;89(1-2):57-64. (PMID: 21620874) ; Pharmacol Ther. 2017 Nov;179:142-157. (PMID: 28546081) ; Aquat Toxicol. 2006 May 25;77(4):422-32. (PMID: 16500718) Grant Information: R01 GM118367 United States GM NIGMS NIH HHS Contributed Indexing: Keywords: 18-HA, adult mice fed with 18 weeks HFD; 18-LA, adult mice fed with 18 weeks LFD; 4-HA, adult mice fed with 4 weeks HFD; 4-LA, adult mice fed with 4 weeks LFD; 7-ER, 7-ethoxyresorufin; 8-HA, adult mice fed with 8 weeks HFD; 8-LA, adult mice fed with 8 weeks LFD; AhR, aryl hydrocarbon receptor; BMI, body mass index; CAR, constitutive androstane receptor; CHZ, chlorzoxazone; CYP2E1, cytochrome P450 2E1; DIO, diet-induced obesity; DMEs, drug-metabolizing enzymes; Diet-induced obesity; Drug-metabolizing enzymes; EFV, efavirenz; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; HFD, high-fat diet; HNF4α, hepatocyte nuclear factor 4 alpha; High-fat diet; LFD, low-fat diet; MDZ, midazolam; MPA, mobile phase A; MPB, mobile phase B; NADPH, nicotinamide adenine dinucleotide phosphate; NAFLD, non-alcoholic fatty liver disease; NRs, nuclear receptors; Nuclear receptors; O-18-HA, offspring from parental mice fed with 18 weeks HFD; O-18-LA, offspring from parental mice fed with 18 weeks LFD; O-4-HA, offspring from parental mice fed with 4 weeks HFD; O-4-LA, offspring from parental mice fed with 4 weeks LFD; O-8-HA, offspring from parental mice fed with 8 weeks HFD; O-8-LA, offspring from parental mice fed with 8 weeks LFD; Ontogenic expression; Overweight; PBS, phosphate-buffered saline; PPARα, peroxisome proliferator-activated receptor alpha; PXR, pregnane X receptor; RSF, resorufin; RT-qPCR, real-time quantitative PCR; SD, standard deviation; SULT1A1, sulfotransferase 1A1; UGT1A1, uridine diphosphate glucuronosyltransferase 1A1 Entry Date(s): Date Created: 20200130 Latest Revision: 20240328 Update Code: 20240329 PubMed Central ID: PMC6976990

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Impact of obese levels on the hepatic expression of nuclear receptors and drug-metabolizing enzymes in adult and offspring mice.